ChitogenX (TSE:CHGX) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ChitogenX Inc., a clinical-stage regenerative medicine company, has reported a decrease in net loss and a significant reduction in research and development (R&D) as well as administrative expenses for the second quarter of 2025. The company is actively seeking development partners and funding for regulatory development, while strategically advancing grant-supported research. These efforts are part of ChitogenX’s commitment to its novel therapeutic tissue repair technologies and to securing non-dilutive funding sources.
For further insights into TSE:CHGX stock, check out TipRanks’ Stock Analysis page.